Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market session. The company's market cap stands at $66.4 million. ProMIS Neurosciences (NASDAQ:PMN) shares increased byread more...

CI's Q2 earnings are likely to face pressure from fewer insured medical customers and a higher MCR despite expected revenue growth.

UHS heads into Q2 with higher admissions and revenue growth expected, but rising labor and operating costs may limit earnings upside.

THC's Q2 performance is likely to have witnessed lower patient days, but higher revenue per admission and Ambulatory Care growth could help offset the pressure.

HCA faces Q2 earnings uncertainty as rising expenses and fewer outpatient surgeries may offset admission growth.

MOH faces lower Marketplace revenues and membership ahead of Q2 results, while Medicaid and Medicare premium growth may offset some pressure.

Community Health heads into Q2 earnings with mixed operating trends as stronger occupancy meets lower admissions and a smaller hospital portfolio.

ELV faces Q2 pressure as weaker Health Benefits results and higher benefit expenses may weigh on earnings ahead of its July 15 report.

The mean of analysts' price targets for Promis Neurosciences (PMN) points to a 230.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.